Recent data highlight a complex competitive landscape in anti-obesity pharmaceuticals. Eli Lilly’s oral GLP-1 agonist orforglipron reported weight loss around 11% after 72 weeks, falling short of injectable rivals like Novo Nordisk’s Wegovy and Lilly’s own Zepbound, which demonstrated 15–21% weight loss. Despite modest outcomes, Lilly anticipates regulatory submissions soon. Novo Nordisk faces challenges from emerging competitors and legal actions aimed at compounding of its GLP-1 compounds, which threaten market share. The rapid growth of this segment has stimulated investment and strategic shifts among major pharma companies.